Amgen's Blincyto, or blinatumomab, received a recommendation for approval from the National Institute for Health and Care Excellence as a treatment for patients with acute lymphoblastic leukemia who are in first complete remission with minimal residual disease activity of 0.1% or more. The cost regulator considered the therapy cost-effective.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.